FDA speeds orphan drugs

"People who suffer with rare diseases are too often faced with no, or limited, treatment options, and what treatment options they have may be quite expensive due in part to significant costs of developing therapies for smaller populations," said FDA Commissioner Scott Gottlieb, MD, in a pr...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2017-07, Vol.161 (7), p.38
Main Author: Hamm, Nicholas
Format: Magazinearticle
Language:English
Subjects:
Biotechnology industry
Drug overdose
FDA approval
Gottlieb, Scott
Mandatory drug testing
Orphan drugs
Rare diseases
Tactical units
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:"People who suffer with rare diseases are too often faced with no, or limited, treatment options, and what treatment options they have may be quite expensive due in part to significant costs of developing therapies for smaller populations," said FDA Commissioner Scott Gottlieb, MD, in a press release. In addition...
ISSN:0012-6616
1937-8157